Shi Guibao

Bristol Myers Squibb (BMS), often referred to in China as Shi Guibao, is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. The company maintains a significant presence in oncology, hematology, immunology, and cardiovascular disease, with a portfolio featuring blockbuster treatments such as Opdivo, Eliquis, and Revlimid. In China, the company operates through various entities including the Sino-American Shanghai Squibb Pharmaceuticals joint venture, which was one of the first Sino-American pharmaceutical JVs established. BMS continues to expand its pipeline through strategic acquisitions, such as Celgene and Karuna Therapeutics, to advance next-generation cell therapies and neuroscience treatments.